We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Compugen Announces Planned Relocation of Headquarters to Larger Facilities
News

Compugen Announces Planned Relocation of Headquarters to Larger Facilities

Compugen Announces Planned Relocation of Headquarters to Larger Facilities
News

Compugen Announces Planned Relocation of Headquarters to Larger Facilities

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Compugen Announces Planned Relocation of Headquarters to Larger Facilities"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Compugen Ltd. has announced the planned relocation by year-end of its Tel-Aviv headquarters, along with its Israeli research and discovery operations, to substantially larger facilities.

The new facilities, now being prepared according to Compugen’s specifications, will support the ongoing growth of the Company and the further advancement of its novel immune checkpoint programs for cancer immunotherapy. The new facilities will be located in the Azrieli Holon Business Center about 12 miles south of Compugen’s current location and will double the available space for the Company’s corporate offices and labs.

This planned expansion follows last year’s relocation of the Company’s wholly-owned US subsidiary, which is focused on the development of antibody therapeutics against the Company’s novel drug targets, to a larger facility in South San Francisco.

Dr. Cohen-Dayag, President and CEO of Compugen, stated, “These larger and enhanced facilities in both Israel and the US are essential for us as we continue to advance a number of our early-stage immuno-oncology novel therapeutic programs, while, at the same time, continuing to enhance and extend our unique, broadly applicable, predictive discovery infrastructure.”

Advertisement